Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Moderna, Inc. — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $25.54 (market cap $142.30B), while Moderna, Inc. trades at $67.13 (market cap $26.76B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 5.3× Moderna, Inc.'s market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.2% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| BBVA | MRNA | |
|---|---|---|
Market Cap | $142.30B | $26.76B |
Sector | Financials | Health |
52-Week High | $26.14 | $81.80 |
52-Week Low | $14.73 | $22.36 |
Dividend Yield | 4.2% | — |
Enterprise Value | — | $22.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $25.39, down 1.17% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 26.51% net income margin and 18.67% ROE. Recent earnings beat expectations in Q1 2026, and revenue has grown steadily from $28.2B in 2022 to $39.4B in 2025. Positive analyst sentiment is reflected in a 53.85% buy rating, though legal and regulatory risks from ongoing probes in Spain present headwinds.
The outlook for BBVA remains positive given robust profitability and analyst support, but investors should weigh the stock's attractive valuation against litigation risks and sector volatility. Upside potential exists if earnings continue to exceed forecasts, but legal developments could pressure the share price near-term.
Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.
While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
